Cystic fibrosis nursing: complete reference guide for students

Cystic fibrosis (CF) is a multisystem, autosomal recessive disease caused by mutations in the CFTR gene. It affects roughly 40,000 people in the United States and remains one of the most clinically complex conditions nursing students encounter — spanning pulmonology, gastroenterology, endocrinology, infectious disease, and transplant medicine. This reference covers the pathophysiology, pulmonary management, CFTR modulators, gastrointestinal care, infection control principles, and high-yield NCLEX testing points. CF is no longer simply a pediatric disease — median survival has extended past 50 years, meaning nurses across all settings will care for CF patients. Use this alongside pediatric nursing reference, pneumonia nursing, and diabetes mellitus nursing for the clinical context this condition requires.

Pathophysiology

CFTR gene mutation and inheritance

CF results from mutations in the CFTR gene (cystic fibrosis transmembrane conductance regulator), located on chromosome 7. The CFTR protein functions as a chloride channel on epithelial cell surfaces. When this channel is absent, misfolded, or dysfunctional, chloride ions cannot move out of the cell normally. Sodium follows chloride; water follows sodium. The result is dehydrated, thick, viscous secretions in every organ system that lines its surfaces with mucus.

Inheritance is autosomal recessive: both parents must carry at least one mutated CFTR allele, and the child must inherit a mutated copy from each parent. Carriers (one functioning allele, one mutated) are phenotypically normal but can pass the mutation on. When two carriers have children, each pregnancy carries a 25% chance of CF, 50% chance of carrier status, and 25% chance of neither allele.

CFTR mutations

Over 2,000 CFTR mutations have been identified, grouped into six classes based on their mechanism of dysfunction. The most clinically significant mutations for nursing students are:

• ΔF508 (delta F508): The most common mutation — present in approximately 70% of US CF patients on at least one allele. It causes the CFTR protein to misfold and be degraded before reaching the cell surface (class II: processing defect).
• G551D: A gating mutation (class III) — the protein reaches the cell surface but the channel fails to open. Responds to ivacaftor (Kalydeco).
• W1282X: A nonsense mutation producing a premature stop codon, resulting in little to no functional CFTR protein.
• N1303K: A processing defect mutation, less common than ΔF508 but clinically similar in presentation.

Mutation class determines which CFTR modulators are effective — a critical distinction in modern CF pharmacology.

Organ systems affected

Impaired chloride transport and dehydrated secretions affect multiple organ systems:

• Lungs (primary): Thick mucus obstructs airways, trapping bacteria and triggering chronic infection and inflammation. Progressive bronchiectasis (permanent airway dilation) develops over time. Pulmonary disease is the primary cause of morbidity and mortality in CF.
• Pancreas: Thick secretions block pancreatic ducts, causing autodigestion. Most CF patients have exocrine pancreatic insufficiency, leading to fat malabsorption and fat-soluble vitamin deficiency.
• GI tract: Thick intestinal secretions predispose to meconium ileus at birth and distal intestinal obstruction syndrome (DIOS) in older patients.
• Reproductive system: Males with CF have congenital bilateral absence of the vas deferens (CBAVD) — most are infertile. Females have reduced fertility due to thickened cervical mucus.
• Sweat glands: Defective chloride reabsorption in sweat ducts results in abnormally high sweat chloride — the basis of the diagnostic sweat chloride test.
• Liver: Biliary cirrhosis can develop from bile duct obstruction; less common than pulmonary and pancreatic complications.

Pulmonary manifestations and management

Obstructive lung disease

CF produces a chronic obstructive pattern on spirometry: reduced FEV1 (forced expiratory volume in one second), reduced FVC, and a normal or reduced FEV1/FVC ratio. Air trapping, hyperinflation, and bronchiectasis develop progressively over years. FEV1 percent predicted is the primary metric used to track disease progression and guide transplant referral.

Airway clearance therapy

Airway clearance is a cornerstone of CF management — performed daily regardless of symptoms and increased in frequency during pulmonary exacerbations. The goal is to mobilize thick mucus from peripheral airways so it can be expectorated or swallowed. The sequence matters: bronchodilator first, then airway clearance, then nebulized dornase alfa or inhaled antibiotics.

Techniques include:

• High-frequency chest wall oscillation (HFCWO / vest therapy): An inflatable vest connected to an air-pulse generator delivers rapid chest wall compressions (5–25 Hz), loosening mucus from airway walls. Typically performed twice daily, 20–30 minutes per session.
• Autogenic drainage (AD): A breathing technique using controlled inspiration and expiration at different lung volumes to progressively move mucus from peripheral to central airways. Requires significant patient training but is device-independent.
• Active cycle of breathing technique (ACBT): Alternates breathing control, thoracic expansion exercises, and forced expiration technique (huffing) to mobilize and clear secretions.
• Postural drainage and percussion (PDP): Traditional gravity-assisted positioning combined with manual chest percussion. Less commonly used as the primary technique in adults but remains in use, particularly in pediatric and home care settings.

Bronchodilators and mucolytics

• Albuterol (short-acting beta-2 agonist): Given before airway clearance to open airways and maximize mucus mobilization. Do not skip this step — bronchospasm can occur with hypertonic saline in sensitized patients.
• Dornase alfa (Pulmozyme, DNase): A recombinant human DNase enzyme that cleaves extracellular DNA in CF sputum — DNA released from neutrophils killed during chronic infection dramatically increases sputum viscosity. Given via nebulizer, typically once daily. Administer after airway clearance so it can penetrate mobilized secretions; it is not a bronchodilator and does not substitute for airway clearance.
• Hypertonic saline (7%): Draws water into the airway surface liquid by osmosis, rehydrating the mucus layer and improving mucociliary clearance. Given by nebulizer after bronchodilator. Can cause bronchospasm — pretreat with albuterol.

Chronic infection suppression

Chronic pulmonary infection is universal in CF. Common organisms progress in a predictable pattern:

• S. aureus (including MRSA) — common in early childhood
• Haemophilus influenzae — early respiratory colonizer
• Pseudomonas aeruginosa — dominant pathogen in adults; once established, essentially impossible to eradicate; suppressed rather than cured

Chronic suppressive therapy for Pseudomonas aeruginosa includes:

• Inhaled tobramycin (TOBI): 28 days on, 28 days off, cycling indefinitely
• Azithromycin (250–500 mg three times weekly): Has anti-inflammatory and immunomodulatory properties beyond its antibiotic effect; reduces exacerbation frequency

Pulmonary exacerbation

A pulmonary exacerbation is an acute worsening of respiratory status requiring intensified treatment. Diagnostic criteria include increased cough, increased sputum production or change in sputum character, new or increased hemoptysis, increased dyspnea, fatigue, fever, anorexia and weight loss, and decline in FEV1 ≥10% from baseline.

Management requires IV antibiotics (selected by sputum culture and sensitivity), intensified airway clearance (up to four times daily), and nutritional support. Common IV antibiotic combinations target Pseudomonas (e.g., tobramycin + piperacillin-tazobactam, or ceftazidime + tobramycin). Courses typically run 14–21 days. See pneumonia nursing for context on nursing care during acute respiratory infections.

CFTR modulators

CFTR modulators are disease-modifying therapies that target the underlying protein dysfunction — not just the downstream consequences. They represent a fundamental shift in CF treatment over the past decade. However, they are mutation-specific and do not work for all patients.

NCLEX tip 1: Trikafta improves CFTR function significantly but does not cure CF. Patients on Trikafta still require daily airway clearance therapy, PERT with meals, and routine monitoring. Discontinuing airway clearance after starting Trikafta is a common patient misconception — correct it proactively.

NCLEX tip 2: CFTR modulators work only for specific mutations. Ivacaftor works for gating mutations like G551D — it is ineffective in ΔF508 patients on its own because the protein never reaches the cell surface. The corrector must bring the protein to the surface before the potentiator has anything to act on.

The complex pharmacology of CFTR modulators and their CYP3A interactions make CF an excellent topic for pharmacology study guides and drug classification review.

Pancreatic and gastrointestinal management

Exocrine pancreatic insufficiency

Approximately 85–90% of CF patients have exocrine pancreatic insufficiency (EPI). Blocked pancreatic ducts prevent digestive enzymes from reaching the small intestine, causing:

• Fat malabsorption — steatorrhea (oily, foul-smelling stools), weight loss, failure to thrive in children
• Fat-soluble vitamin deficiency — vitamins A, D, E, and K are all affected (remember: ADEK). Vitamin K deficiency increases bleeding risk; vitamin D deficiency contributes to CF-related bone disease.
• Protein malabsorption — contributes to low muscle mass and impaired growth

Pancreatic enzyme replacement therapy (PERT)

PERT is prescribed by lipase units (not capsule count) per meal. Standard dosing ranges from 500–4,000 lipase units per kilogram per meal, with a maximum of 10,000 lipase units/kg/day (higher doses are associated with fibrosing colonopathy). Snacks require approximately half the meal dose.

Critical nursing and patient education points:

• PERT must be taken with food — not before sitting down, not after finishing the meal. The enzymes must mix with food in the stomach to be effective.
• Capsules can be opened and the beads mixed with acidic foods (applesauce, pureed fruit) for young children who cannot swallow capsules. Do not crush the beads.
• Fat-soluble vitamins (ADEK) are supplemented in water-miscible formulations — standard vitamin preparations are oil-based and poorly absorbed in EPI.

CF-related diabetes (CFRD)

CF-related diabetes affects approximately 20% of adolescents and 40–50% of adults with CF. It is distinct from type 1 and type 2 diabetes:

• Mechanism: Fibrosis progressively destroys pancreatic islet cells (both beta and alpha cells), causing insulin deficiency. Peripheral insulin resistance is less prominent than in type 2 diabetes.
• Treatment: Insulin — always. Oral hypoglycemic agents (metformin, sulfonylureas, GLP-1 agonists) are not effective and are not recommended. This is a critical distinction from type 2 diabetes management.
• Hypoglycemia: Less common than in type 1 or insulin-treated type 2 diabetes because residual alpha cell function (glucagon secretion) is partially preserved early in CFRD. However, tight control and missed meals can still cause hypoglycemia.
• Monitoring: HbA1c underestimates glycemic burden in CF due to high red cell turnover — fasting and postprandial glucose monitoring is preferred.
• Nutritional context: CF patients require 110–200% of normal daily caloric intake. A caloric-restricted diabetes diet appropriate for type 2 patients is dangerous in CF — never restrict calories in a CF-CFRD patient.

Refer to diabetes mellitus nursing for core insulin management principles, keeping in mind the CFRD-specific distinctions above.

Meconium ileus and DIOS

Meconium ileus — bowel obstruction from thick, inspissated meconium — occurs in 10–15% of CF neonates and is often the first presentation of CF. It presents as failure to pass meconium within 48 hours of birth, abdominal distension, and bilious vomiting. Approximately 90% of meconium ileus cases are associated with CF.

Distal intestinal obstruction syndrome (DIOS) is the older-patient equivalent — a partial or complete obstruction of the ileocecal region from inspissated intestinal contents. Presents with crampy right lower quadrant pain, abdominal fullness, and a palpable mass in the right iliac fossa. Management includes oral polyethylene glycol (PEG) solution, Gastrografin enema, or IV fluid hydration.

Infection control

Infection control in CF requires strict adherence to principles that go beyond standard precautions. The same respiratory pathogens that colonize one CF patient can be transmitted to another, causing devastating consequences.

Common organisms and clinical significance

Cohorting and segregation principles

CF patients must never share air space with other CF patients. This is not a preference — it is a safety standard. Specific requirements include:

• Separate waiting rooms: CF patients should not wait in shared clinic waiting rooms. Many CF centers use a “room-to-room” model where patients are taken directly to examination rooms upon arrival.
• No CF camps or group activities: Social gatherings of CF patients carry documented transmission risk, particularly for Pseudomonas and Burkholderia.
• No shared nebulizers or airway clearance equipment: Device-sharing between CF patients is prohibited.
• Cohorting by organism: Patients colonized with Burkholderia cepacia or NTM should be cohorted away from other CF patients even within the same unit. In hospital settings, patients with Bcc should ideally be in private rooms on separate units from other CF patients.

Standard precautions apply to all CF patients. Contact and droplet precautions apply when Pseudomonas, MRSA, or Burkholderia are present.

NCLEX tip 3: Burkholderia cepacia is the organism most critical to remember for infection control NCLEX questions. CF patients colonized with Bcc must never be placed in rooms adjacent to or shared with other CF patients — not even in hallways or shared bathrooms. This is distinct from standard droplet precaution logic and tests higher-order infection control thinking.

Diagnostic testing and newborn screening

Newborn screening

Universal newborn screening for CF occurs in all 50 US states. The screening protocol:

1. Immunoreactive trypsinogen (IRT): Elevated IRT in a newborn’s dried blood spot (heel stick) indicates possible CF — blocked pancreatic ducts cause trypsinogen to leak into the bloodstream. IRT is a screening marker, not diagnostic.
2. DNA mutation analysis: If IRT is elevated, the same blood spot is tested for a panel of CFTR mutations. Two mutations identified = refer for confirmatory testing. One mutation identified = refer for confirmatory testing. No mutations with elevated IRT = repeat IRT at 2 weeks.
3. Confirmatory sweat chloride test: Required to confirm diagnosis regardless of genetic results.

NCLEX tip 4: The correct sequence for CF newborn screening is IRT first, then DNA mutation panel on the same or repeat specimen, then sweat chloride for confirmation. The sweat chloride test is the definitive diagnostic test — newborn screening identifies who needs the sweat chloride test, not the diagnosis itself.

Sweat chloride test

The sweat chloride test (pilocarpine iontophoresis) is the gold standard for CF diagnosis. Pilocarpine is applied to the forearm via mild electrical current to stimulate sweat production, which is then collected and analyzed.

• ≥60 mEq/L: Diagnostic for CF
• 30–59 mEq/L: Borderline — repeat testing and genetic analysis required
• <30 mEq/L: CF unlikely

NCLEX tip 5: The diagnostic threshold for sweat chloride is ≥60 mEq/L — not just “elevated.” Values between 30 and 59 are borderline and require additional workup. This specific cutoff is frequently tested.

Nursing priorities and monitoring

Respiratory monitoring

• Oxygen saturation (SpO2): Target ≥90% at baseline; many patients with advanced disease have chronically lower saturations that they tolerate without supplemental oxygen. Baseline values must be established for each patient — do not apply population norms to CF patients with known baseline impairment.
• FEV1 percent predicted: The primary metric for tracking disease progression. A decline of ≥10% from personal best triggers evaluation for exacerbation. FEV1 <30% predicted triggers referral for lung transplant evaluation.
• Sputum cultures: Track organism changes — new organisms (especially first Pseudomonas or Burkholderia) require prompt treatment and infection control review.
• Hemoptysis: Minor hemoptysis is common in CF (bronchiectatic vessels bleed easily). Massive hemoptysis (>240 mL/24 hours) is a medical emergency — hold airway clearance, position patient with bleeding side down, notify physician immediately.

Nutritional assessment

Nutritional deficits are universal in CF and accelerate lung function decline. Every patient encounter should include:

• Weight and height (BMI percentile in children)
• Fat-soluble vitamin levels: retinol (A), 25-hydroxyvitamin D, alpha-tocopherol (E), prothrombin time/INR (K deficiency indicator)
• Assessment of PERT adherence and dosing adequacy
• Assessment of oral intake and appetite changes

CF patients require 110–200% of normal daily caloric requirements due to malabsorption, increased work of breathing, and chronic infection. High-calorie, high-fat diets are appropriate — not restricted.

Mental health

CF is a progressive, life-limiting disease diagnosed in childhood. Depression and anxiety rates in the CF population are approximately two to three times higher than general population rates. Screening for depression and anxiety should occur at every care encounter. Transitions of care — particularly from pediatric to adult CF programs — are high-risk periods for mental health deterioration.

Pulmonary exacerbation monitoring table

Nutrition and pancreatic enzyme management

Lung transplantation

Indications

Bilateral sequential lung transplant is considered when:

• FEV1 falls below 30% predicted
• Rapid rate of FEV1 decline despite optimal medical therapy
• Recurrent life-threatening hemoptysis unresponsive to embolization
• Hypercapnic respiratory failure (PaCO2 rising despite optimization)
• Increasing oxygen requirements

Both lungs must be replaced — a single-lung transplant is not performed in CF because the remaining diseased CF lung would cross-contaminate the donor lung with Pseudomonas and other organisms.

Post-transplant CF considerations

NCLEX tip 6: CF does not recur in transplanted lungs. The donor lungs carry the donor’s CFTR genotype — they have functioning CFTR proteins. However, CF remains a systemic disease: the recipient’s sinuses, pancreas, GI tract, and sweat glands still have the CFTR mutation. Airway clearance for sinuses, PERT, CFRD management, and fat-soluble vitamin supplementation all continue post-transplant.

Patients colonized with Burkholderia cepacia complex — particularly B. cenocepacia — have significantly higher post-transplant mortality. Some transplant centers decline listing patients with B. cenocepacia. This is a critical consideration when counseling CF patients about infection control and cohorting compliance.

High-yield NCLEX tips

NCLEX tip 7: Sweat chloride diagnostic threshold Sweat chloride ≥60 mEq/L = diagnostic for CF. Values between 30 and 59 are borderline and require repeat testing plus genetic analysis. Values <30 mEq/L make CF unlikely. The specific threshold of 60 is the number to know.

NCLEX tip 8: Autosomal recessive inheritance CF is autosomal recessive. Both parents must carry at least one mutated CFTR allele. When two carriers have children, each pregnancy carries a 25% chance of CF, 50% chance of carrier status, 25% chance of normal genotype. A child with CF does not mean subsequent children will also have CF — each pregnancy is independent (Mendel’s law of independent assortment).

NCLEX tip 9: Airway clearance sequence The correct sequence for CF inhaled therapy is: (1) albuterol (bronchodilator — opens airways), (2) airway clearance (vest, AD, ACBT, or percussion), (3) dornase alfa or hypertonic saline (penetrates now-mobilized mucus), (4) inhaled antibiotics (tobramycin, aztreonam) last, to maximize antibiotic delivery to cleared airways. Reversing this sequence reduces therapeutic effectiveness.

NCLEX tip 10: PERT with food Pancreatic enzyme replacement therapy must be taken with food — not before the first bite, not after the last bite. The enzymes must be present in the stomach simultaneously with food to work. A patient who takes PERT before sitting down to eat or after finishing a meal is not getting full therapeutic benefit.

NCLEX tip 11: Burkholderia cepacia = strict segregation CF patients colonized with Burkholderia cepacia must never share air space with other CF patients — separate waiting rooms, separate clinic days, private hospital rooms on different floors from other CF patients. B. cenocepacia in particular is associated with rapid lung function decline (“cepacia syndrome”) and post-transplant mortality. This is higher-stakes than standard droplet precaution scenarios.

NCLEX tip 12: CFRD treated with insulin only CF-related diabetes is treated with insulin. Oral hypoglycemic agents (metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists) are not effective in CFRD and are not recommended. This is a key distinction from type 2 diabetes management — if an NCLEX question asks about CFRD management, insulin is always the correct answer for pharmacologic treatment.

NCLEX tip 13: Trikafta is not a cure Elexacaftor/tezacaftor/ivacaftor (Trikafta) improves CFTR function at the cellular level and produces dramatic clinical improvements for eligible patients (those with at least one ΔF508 allele). It is not a cure. Airway clearance, PERT, infection monitoring, and all other CF management continues. Patients who stop airway clearance after starting Trikafta are at risk for exacerbation.

NCLEX tip 14: Newborn screening sequence CF newborn screening uses IRT (immunoreactive trypsinogen) from a heel-stick blood spot as the initial screen. A positive IRT prompts DNA mutation analysis. Confirmatory diagnosis requires a sweat chloride test. The IRT elevation occurs because blocked pancreatic ducts cause trypsinogen to leak into the bloodstream — it is a consequence of EPI, not a direct measure of CFTR function.

NCLEX tip 15: Lung transplant — both lungs required In CF, bilateral sequential lung transplant is required — not single-lung. If only one CF lung is replaced, the remaining diseased lung’s chronic Pseudomonas colonization will contaminate the donor lung. Single-lung transplant is inappropriate in CF.

Summary: clinical priorities for CF nursing

Caring for a patient with CF requires simultaneous attention to respiratory, nutritional, endocrine, infectious, and psychosocial domains. Airway clearance is daily, lifelong, and non-negotiable. Nutrition is as critical as pulmonary function — underweight CF patients have faster FEV1 decline. CFTR modulators have transformed the disease trajectory for most patients, but require ongoing monitoring (LFTs, cataracts, drug interactions) and do not eliminate the need for standard CF care.

Infection control is a patient safety issue beyond the individual — CF patients who acquire Burkholderia cepacia from another CF patient face a fundamentally different disease trajectory. Strict cohorting policies protect every CF patient in a shared healthcare environment.

For a broader view of respiratory pharmacology covered in CF management, see pharmacology study guide and drug classifications. For end-stage respiratory failure context, see ARDS nursing.

Clinical content reviewed against: Cystic Fibrosis Foundation (CFF) Clinical Practice Guidelines; NCBI/PubMed CF pathophysiology and CFTR modulator literature; NIH MedlinePlus CF reference; Up-to-Date CF management guidelines. All drug information reflects current US prescribing information.